Agaricus Blazei Murill (ABM) in Patients With Inflammatory Bowel Disease (IBD)

Ullevaal University Hospital

Status and phase: Completed; Phase 2

Conditions: Inflammatory Bowel Disease

Treatments: Dietary Supplement: AndoSan

Study type: Interventional

Funder types: Other

Identifiers

NCT01106742

AbM2009-IBD

Details and patient eligibility

About

Based on the anti-inflammatory and stabilising effect of the AbM, (Agaricus Blazei Murill) based mushroom extract AndoSanTM on cytokine release in blood in vivo and ex vivo in healthy volunteers after 12 days consumption, the aim in this study is to investigate whether same effect is valid in patients with IBD (inflammatory bowel disease). In addition, calprotectin an abundant cytosolic protein in neutrophils and a surrogate marker for degree of intestinal inflammation will be measured in blood and feces of these patients.

Enrollment: 20 patients

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Moderate disease activity

Exclusion criteria

• No use of Imurel (Azathioprin) or anti-TNF treatment

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

20 participants in 2 patient groups

AndoSan, UC

Experimental group

Description:

AndoSan as a supplement to 10 UC patents

Treatment:

Dietary Supplement: AndoSan

AndoSan, CD

Experimental group

Description:

AndoSan as a supplement to 10 CD patients.

Treatment:

Dietary Supplement: AndoSan